Last reviewed · How we verify
SARS-COV-2 VIRUS, INACTIVATED
At a glance
| Generic name | SARS-COV-2 VIRUS, INACTIVATED |
|---|---|
| Modality | Vaccine component |
| Phase | FDA-approved |
| First approval | 2022 |
Approved indications
Common side effects
Key clinical trials
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Vaccine Responses in Cancer
- Covid-19 and Influenza Oral Vaccine Study (PHASE1)
- Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-COV-2 VIRUS, INACTIVATED CI brief — competitive landscape report
- SARS-COV-2 VIRUS, INACTIVATED updates RSS · CI watch RSS